share_log

Avenue Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Fortress Biotech, Inc.

SEC announcement ·  Jan 3 00:00
Summary by Moomoo AI
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more